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Abstract
Introduction—Obesity accelerates the development and progression of pancreatic cancer, though 
the mechanisms underlying this association are unclear. Adipocytes are biologically active, 
producing factors such as hepatocyte growth factor (HGF) that may influence tumor progression. 
We therefore sought to test the hypothesis that adipocyte-secreted factors including HGF 
accelerate pancreatic cancer cell proliferation.
Material and methods—Murine pancreatic cancer cells (Pan02 and TGP-47) were grown in a) 
conditioned medium (CM) from murine F442A preadipocytes, b) HGF-knockdown preadipocyte 
CM, c) recombinant murine HGF at increasing doses, and d) CM plus HGF-receptor (c-met) 
inhibitor. Cell proliferation was measured using the MTT assay. ANOVA and t-test were applied; p 
< 0.05 considered significant.
Results—Wild-type preadipocyte CM accelerated Pan02 and TGP-47 cell proliferation relative 
to control (59 ± 12% and 34 ± 12%, p < 0.01, respectively). Knockdown of preadipocyte HGF 
resulted in attenuated proliferation vs. wild type CM in Pan02 cells (35 ± 5% vs. 68 ± 14% greater 
than control; p < 0.05), but proliferation in TGP-47 cells remained unchanged. Recombinant HGF 
dose-dependently increased Pan02, but not TGP-47, proliferation (p < 0.05). Inhibition of HGF 
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receptor, c-met, resulted in attenuated proliferation versus control in Pan02 cells, but not TGP-47 
cells.
Conclusions—These experiments demonstrate that adipocyte-derived factors accelerate murine 
pancreatic cancer proliferation. In the case of Pan02 cells, HGF is responsible, in part, for this 
proliferation.
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1. Introduction
Obesity portends a poor outcome in numerous cancers, including breast, colon, prostate, and 
others [1]. These poor outcomes include increased cancer development and poorer survival 
among obese individuals relative to lean cohorts of patients. Recent data have shown that 
pancreatic cancer is also negatively affected by obesity. Epidemiologic studies show an 
increased risk of developing pancreatic cancer in obese patients [2–4], and clinical data 
clearly demonstrate that obesity leads to poor outcomes in pancreatic cancer patients [5–8]. 
We recently reported that pancreatic fat is associated with higher rates of lymphatic invasion 
and higher mortality [9]. Despite this substantial body of clinical evidence, virtually no basic 
science investigation has explained the mechanisms underlying the relationship between 
obesity and pancreatic cancer. Our group recently reported the first in vivo model of 
pancreatic cancer in obesity [10]. In this model, lean mice and congenitally obese mice were 
inoculated with murine pancreatic cancer (Pan02) cells. We observed larger, more aggressive 
tumors, as well as higher mortality in the obese mice when compared with the lean animals, 
all of whom developed tumors.
Adipose tissue is a biologically active endocrine organ, secreting numerous cytokines, 
adipokines, and growth factors [11]. Adipocytes and preadipocytes, both present in adipose 
tissue, secrete angiogenic, anti-apoptotic, and mitogenic molecules [12–16] that could 
enhance tumor growth. One of these molecules is hepatocyte growth factor (HGF). 
Hepatocyte growth factor is known in the endocrine literature as a potent mitogenic and 
angiogenic growth factor for adipose tissue [15], working synergistically with vascular 
endothelial growth factor (VEGF) to induce endothelial cell migration [17]. HGF production 
from adipocytes and preadipocytes is significant, leading to elevated systemic levels of HGF 
in obesity [18]. In the cancer literature, HGF is known to stimulate tumor proliferation in 
several types of cancer, including pancreatic cancer, through its only known receptor, c-met 
[19–23]. Stromal fibroblasts, which are important in pancreatic adenocarcinoma biology, 
also have been shown to secrete HGF [19]. Based on this background and the striking results 
of our in vivo model of obesity and pancreatic cancer, we developed an in vitro model to 
investigate potential mechanisms of obesity’s effect on pancreatic cancer. We hypothesized 
that adipocyte-derived factors, including HGF, would accelerate pancreatic cancer cell 
growth.
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2. Material and methods
2.1. Cell lines
Two murine pancreatic cancer cell lines, Pan02 (gift of Dr. David Linehan, Washington 
University, St. Louis, MO) and TGP-47 (ATCC, Manassas, VA) were studied. Pan02 cells 
were grown in high glucose (4 g/l) Dulbecco’s Modified Essential Medium (DMEM; Sigma, 
St. Louis, MO) + 10% Fetal Bovine Serum (FBS; Cellgro, Manassas, VA) containing 1% 
penicillin/streptomycin (Thermo Scientific, Waltham, MA). TGP-47 cells were grown in 
DMEM + 10% FBS + pen/strep + growth factor F-12 (Sigma). TGP-47 cells were switched 
to the Pan02 medium 1 passage prior to each experiment. Murine 3T3-F442A preadipocytes 
(a generous gift from Howard Green, Harvard University, Cambridge, MA) were maintained 
as previously published [15] in high glucose DMEM+ 10% bovine calf serum (BCS, Sigma) 
+0.2% penicillin/streptomycin. Wild type 3T3-F442A preadipocytes were induced to 
differentiate into mature adipocytes by switching to medium containing 10%FBS and adding 
0.01 μg/ml insulin (Sigma).
2.2. HGF knockdown
In order to create an HGF knockdown cell line, 3T3-F442A cells at ~70% confluence were 
infected with commercially available puromycin resistance-containing lentivirus shRNA 
reagents targeting murine HGF (MissionTM TRC shRNA Lentiviral Target Set, Sigma 
Aldrich). Scrambled shRNA was used as control. Following treatment with puromycin, 
surviving clones were picked and screened for HGF knockdown by mRNA expression and 
protein production. A clonal line was established that had 93% knockdown of HGF mRNA 
(1.89 vs 25.3 relative units) and 99% reduction in protein secretion (0.13 ng/ml/24 h vs 9.6 
ng/ml/24 h). Specific details regarding the knockdown methodology have been published 
previously [15].
2.3. Preparation of conditioned medium
To prepare conditioned medium, 3T3-F442A cells with and without HGF knockdown and 
Pan02 cells (as a control) were grown to 70–80% confluence for 72 h. Medium was 
collected, centrifuged to remove debris, aliquotted, and frozen at −80 °C. Conditioned 
medium from F442A preadipocytes is referred to as “wild type” medium, that collected 
from HGF knockdown cells is referred to as “knockdown” medium, and medium 
conditioned by Pan02 cells is considered “control” unless otherwise specified.
2.4. Measurement of pancreatic cancer cell growth
To assess cancer cell proliferation under various conditions, Pan02 cells were plated onto a 
96 well plate (Corning, Corning, NY) at a concentration of 5000 cells/well and allowed to 
adhere for 24 h. TGP-47 cells were plated at a concentration of 5000 cells/well and allowed 
to adhere for 8 h. Total volume of medium in the well was 100 μl. At the end of the 
adherence period 50 μl of medium was removed from each well, 50 μl of the various 
conditioned medium was added, and the cells were permitted to proliferate for 24 h. This 
time point was chosen based on our previous work [15]. During the last 4 h of the growth 
period, cell proliferation was measured using the 3-[4,5-dimethyl-thazol-2-yl]-2,5-
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diphneyltetrazolium-bromide (MTT) assay (Roche Applied Diagnostics, Manheim, 
Germany). Each proliferation condition was tested in quadruplicate wells or greater, and 
each experiment was repeated at least four separate times with each cell line at a different 
passage number.
2.5. HGF dose-response
Recombinant HGF (R&D Systems, Minneapolis, MN) was added to Pan02 (n = 5 repeat 
experiments) and TGP-47 cells (n = 4 repeat experiments) plated as described above, at the 
following doses: 0, 0.1, 1, 10, and 100 ng/ml. After 24 h of growth, the MTT proliferation 
assay was performed as above.
2.6. Inhibition of the HGF receptor, c-met
In order to evaluate the effect of HGF in the conditioned medium, the MTT assay was 
performed using wild-type conditioned medium in combination with 100 nmol of 
PF-02341066 (Selleck Chem, Houston, TX), a specific inhibitor of the HGF receptor, c-met.
2.7. Detection of the HGF receptor, c-met
To examine the presence of c-met on pancreatic cancer cells, RT-PCR and 
immunohistochemistry were performed. Total RNA was isolated from cells and tissues by 
guanidinium thiocyanate-phenol-chloroform extraction, and cDNA was synthesized from 0.5 
ng of total RNA using random hexamers (Applied Biosystems, Foster City, CA) in a 100 μl 
reaction. mRNA levels of all genes investigated were determined by Real-Time RT-PCR 
using iTaq SYBR Green Supermix with ROX (Bio-Rad Laboratories, Hercules, CA) in an 
ABI Prism 7700 Sequence Detection System (Applied Biosystems). Five microliters of 
cDNA (25 ng of total RNA) were amplified in a reaction volume of 25 μl, and cycling 
conditions were one cycle for 2 min at 50 °C and one cycle for 3 min at 95 °C, followed by 
40 cycles of 15 s of denaturation at 95 °C and 1 min of annealing/extension at 60 °C. Primer 
sets (forward 5′ GAATGTCGTCCTACACGGCC-3′ and reverse 5′-
CACTACACAGTCAGGACACTGC-3′; Invitrogen, Carlsbad, CA) were used at a 
concentration of 200 nM. Expression of all genes was normalized to 36B4 (mouse acidic 
ribosomal phosphoprotein) expression using the delta CT method.
Murine c-met immunohistochemistry was performed using C-28 antibody (Santa Cruz 
Biotechnology, Santa Cruz, CA). Pan02, TGP-47, and HEK-293 cells (as a positive control) 
grown on glass slides, were fixed with methanol at −10 °C for 5 min, and washed with PBS 
3 times. The remainder of the processing was performed as specified by the HRP rabbit 
ImmunoCruz Staining System (Santa Cruz Biotechnology, Santa Cruz, CA). Briefly, 
endogenous peroxidase activity was quenched using peroxidase block, followed by 
incubation in normal goat serum. Primary c-met antibody (C-28; Santa Cruz Biotechnology) 
was diluted 1:50 in normal goat serum for a concentration of 4 μg/ml, then added to slides 
and incubated overnight. Negative control slides were not exposed to primary antibody. 
Specimens were then probed with secondary antibody for 30 min, followed by HRP-
streptavidin complex for 30 min. The HRP substrate was then added for 25 min and slides 
were counterstained with hematoxylin (Invitrogen) for 10 s before dehydration and 
mounting.
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2.8. Statistical analyses
All data are expressed as mean ± SEM. Statistical comparisons of conditioned medium 
experiments used paired t-tests, and statistical comparisons of HGF dose response and c-met 
inhibition experiments used ANOVA with post-hoc Tukey comparison. A P value of <0.05 
was considered significant. All statistics were performed using GraphPad Prism Software 
(La Jolla, CA).
3. Results
3.1. Conditioned medium enhances pancreatic cancer cell proliferation
Pan02 murine pancreatic cancer cells were cultured in conditioned medium (CM) from 
undifferentiated (preadipocyte) F442A cells and in CM from F442A cells induced to 
differentiate into mature adipocytes. Undifferentiated preadipocyte medium significantly 
increased Pan02 proliferation over control by 59 ± 12% (p < 0.01). Similarly, differentiated 
adipocyte CM significantly increased Pan02 proliferation by 34 ± 12% over control (p < 
0.01). Further experiments were conducted using F442A preadipocytes. Preadipocyte CM 
also significantly enhanced the proliferation of a second murine pancreatic cancer cell line, 
TGP-47, by 39 ± 5% over control medium (p < 0.01). Thus, preadipocyte CM significantly 
enhanced proliferation of two discrete murine pancreatic cancer cell lines (Fig. 1).
3.2. HGF knockdown medium attenuates adipocyte-mediated pancreatic cancer 
proliferation
Hepatocyte growth factor (HGF) is produced by preadipocytes and is known to be important 
in pancreatic cancer growth [22,23]. Using shRNA techniques, F442A HGF protein 
expression was knocked down by 99%. As shown in Fig. 2A, Pan02 proliferation was 
significantly decreased when grown in the presence of HGF knockdown medium relative to 
growth in wild-type conditioned medium (35 ± 5% vs. 68 ± 14% growth > control; p < 
0.05). In contrast, no significant difference was seen in TGP-47 proliferation when grown in 
HGF knockdown versus wild-type CM (37 ± 4% vs. 40 ± 5% growth > control; p = NS) 
(Fig. 2B).
3.3. Effect of recombinant HGF on pancreatic cancer cell proliferation
Treatment of Pan02 cells with exogenous recombinant HGF resulted in a dose-dependent 
increase in proliferation that was significantly greater than control at doses of 1, 10, and 100 
ng/ml (p < 0.01; Fig. 3A). Exogenous HGF administration did not change TGP-47 
proliferation at the doses tested (Fig. 3B).
3.4. Pharmacologic inhibition of HGF receptor c-met
The tyrosine kinase inhibitor PF02341066 specifically blocks the HGF receptor, c-met. C-
met inhibition significantly decreased Pan02 proliferation (0.81 ± 0.06 vs. 0.71 ± 0.07 
absorbance units; p < 0.05; Fig. 4). Incubation with inhibitor alone did not affect 
proliferation of Pan02 cells (data not shown). TGP-47 cell proliferation was not affected by 
inhibition of the HGF receptor, c-met (p = NS).
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3.5. Detection of c-met
The only known receptor for HGF is the tyrosine kinase c-met. Using Real Time RT-PCR, 
mRNA for the c-met receptor was detected in both Pan02 and TGP-47 cells (CT = 23.5 and 
22.1, respectively), as well as F442A cells (positive control); Fig. 5. Immunohistochemical 
staining demonstrated the presence of c-met receptors on the cell surface of both Pan02 and 
TGP-47 cells (data not shown).
4. Discussion
Obesity significantly affects the growth of pancreatic cancer, as shown in epidemiologic, 
clinical [1,6,9], and in vivo biological studies [10]. The mechanisms underlying this 
association, however, remain unknown. The current experiments show that preadipocyte 
conditioned medium significantly increases proliferation of two distinct murine pancreatic 
cell lines, Pan02 and TGP-47. In Pan02 cells, this accelerated proliferation is reduced when 
hepatocyte growth factor has been attenuated, either by shRNA knockdown or HGF receptor 
inhibition. Exogenous HGF also dose-dependently accelerated the proliferation of the Pan02 
pancreatic cancer cells. In contrast, exogenous HGF did not increase proliferation in TGP-47 
cells; and in turn, TGP-47 proliferation was not affected by decreasing HGF (by shRNA 
knockdown and receptor inhibition). Taken in aggregate, these data suggest that 
preadipocyte-secreted HGF is responsible, in part, for obesity-related accelerated murine 
pancreatic cancer growth. We have previously documented the presence of HGF message as 
well as protein in F442A cells [15]. In addition, silencing of HGF resulted in 83% decrease 
in HGF production [15].
The fact that obesity exerts a negative influence on numerous malignancies, including 
pancreatic cancer, is now well-accepted [1,2]. A substantial body of epidemiologic data 
supports this concept; in addition, several group have reported that obesity increases 
perioperative complications in patients undergoing pancreatectomy for cancer [5,7,8]. 
Moreover, fat in the pancreas has been associated with an increased incidence of pancreatic 
fistula after pancreaticoduodenectomy [24].
Obesity also appears to impact survival of patients with pancreatic cancer. Fleming et al. 
found that relative to lean patients, obese patients with resected pancreatic cancer were 
significantly more likely to develop lymphatic metastases, with decreased disease free and 
overall survival [6]. In addition to generalized adiposity, local pancreatic fat content may 
play a role in this process. In patients matched for BMI (as well as tumor size and grade), 
those with a greater volume of pancreatic fat had more lymphatic metastasis and poorer 
overall survival [9]. A striking observation in our murine model of pancreatic cancer in 
obesity was that tumors developing in obese mice had a greater volume of intratumoral fat 
than tumors growing in lean animals [10]. Preliminary observations have confirmed the 
presence of adipocytes in human pancreatic cancers (unpublished data). Obesity may 
therefore influence pancreatic cancer development and growth at several levels, including 
systemically, locally, and at the level of the tumor microenvironment.
Contemporary understanding of adipocyte biology has shed light on potential mechanisms 
by which obesity influences cancer growth. Once thought to be a storage depot for 
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triglycerides, adipocytes are now recognized as active metabolic cells, producing nearly 100 
proteins that affect metabolism, inflammation, and cell growth [11]. A major finding in the 
current study is that co-culture with preadipocyte conditioned medium significantly 
accelerated the proliferation of two discrete murine pancreatic cancer cell lines. Similar 
observations have been reported in other cancer cell systems [25,26]; to our knowledge, this 
is the first such report involving pancreatic cancer. These data provide strong support for the 
concept that adipocyte-derived factors directly influence the proliferation of pancreatic 
cancer.
One likely component in the interaction between adipocytes and cancer cells is HGF. First 
isolated from hepatocytes, HGF is produced in significant quantity by preadipocytes and 
adipocytes [18]. Adipocyte-derived HGF has mitogenic and angiogenic properties, and HGF 
promotes the growth of several cancers, including pancreatic cancer [19–23]. Exogenous 
HGF within physiologic range increased the proliferation of Pan02 pancreatic cancer cells, 
and knockdown of adipocyte-derived HGF and specific blockade of the only known HGF 
receptor, c-met, both significantly attenuated adipocyte-induced excess Pan02 proliferation. 
The presence of c-met has been documented in pancreatic cancer cells, and understanding of 
it’s role in pancreatic carcinogenesis is evolving [22,23]. While possible that another 
adipocyte-derived protein may be responsible for this excess proliferation, this constellation 
of findings strongly suggests that accelerated Pan02 proliferation is mediated, in part, by 
adipocyte-derived HGF.
On the other hand, neither exogenous HGF administration nor preadipocyte HGF 
knockdown affected TGP-47 proliferation. One possible explanation for this observation is 
that TGP-47 cells do not express the HGF receptor, c-met. Another possible explanation is 
that HGF does not directly affect TGP-47 proliferation but acts through a discrete 
mechanistic pathway such as apoptosis arrest. In the larger picture, differences of HGF 
effect on Pan02 and TGP-47 reflect the innate variability inherent in biological systems. For 
example, while HGF is likely responsible for a portion of the excess adipocyte-induced 
proliferation of Pan02 cells, other adipocyte-derived factors clearly contribute as well. 
Similarly, the current experiments were designed as a logical extension of our murine in vivo 
pancreatic cancer studies, and thus investigated murine preadipocytes and pancreatic cancer 
cells.
In vitro cell culture work has inherent limitations, including differential proliferative 
response to immortalization. Continuation of the current work using human adipocytes and 
pancreatic cancer cells is clearly necessary. Fresh cultured human tumors in murine models 
are also attractive models. Furthermore, cellular proliferation represents just one piece of the 
carcinogenesis puzzle [27]. The influence of adipocyte-derived factors (including HGF) on 
pancreatic cancer migration and invasion remains to be defined.
5. Conclusions
These experiments clearly demonstrate that adipocyte-derived factors accelerate murine 
pancreatic cancer proliferation. In the case of Pan02 cells, adipocyte-induced excess 
proliferation is mediated, in part, by a HGF mechanism. Further elucidation of the pathways 
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by which adipocytes influence pancreatic cancer growth may identify novel targets for 
directed therapy [28].
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HIGHLIGHTS
• Adipocyte conditioned media accelerated pancreatic cancer cell proliferation.
• Knockdown of adipocyte hepatocyte growth factor (HGF) attenuated 
pancreatic cell proliferation.
• Recombinant HGF dose-dependently increased proliferation of Pan02 
pancreatic cancer cells.
• Inhibition of HGF receptor (c-met) attenuated proliferation of Pan02 
pancreatic cancer cells.
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Fig. 1. 
Murine pancreatic cancer cells, Pan02 and TGP-47 were incubated with conditioned 
medium (CM) from F442A preadipocytes. Proliferation was measured using the MTT assay. 
Values represent mean ± SEM for 8 separate experiments in Pan02 cells and 7 separate 
experiments in TGP-47 cells. *p < 0.01 vs. control medium.
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Fig. 2. 
Murine pancreatic cancer cells Pan02 (A) and TGP-47 (B) were incubated with wild type 
preadipocyte conditioned medium (CM) and HGF knockdown CM. Values represent mean ± 
SEM for 6 separate experiments with Pan02 cells and 7 separate experiments with 
TGP-47.*p < 0.05 vs. wild-type.
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Fig. 3. 
Murine pancreatic cancer cells Pan02 (A) and TGP-47 (B) were incubated with increasing 
concentrations of exogenous HGF. Values represent mean ± SEM of 5 separate experiments 
with Pan02 and 4 separate experiments with TGP-47 cells. *p < 0.01 vs. “none” (control).
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Fig. 4. 
Proliferative effects of preadipocyte conditioned medium (CM) on Pan02 cells are reduced 
in the presence of the c-met inhibitor, PF-02341066. Values represent mean ± SEM for 4 
separate experiments. *p < 0.05 vs. Adipocyte CM.
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Fig. 5. 
rtPCR documents presence of receptor c-met on Pan02 and TGP47 cells (as well as F442A 
cells as positive control).
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